Analyst Price Target is $6.67
▲ +178.94% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $6.67, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 178.94% upside from the last price of $2.39.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in VistaGen Therapeutics. This Buy consensus rating has held steady for over two years.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder (SAD); PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD); and AV-101 which the company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.